Chapter 10. Receptor Targeting of Adeno-Associated Virus Vectors

  1. David T. Curiel M.D. and
  2. Joanne T. Douglas Ph.D.
  1. Hildegard Büning Ph.D.,
  2. Martin Ulrich Ried Ph.D. and
  3. Michael Hallek M.D.

Published Online: 31 MAR 2003

DOI: 10.1002/0471234303.ch10

Vector Targeting for Therapeutic Gene Delivery

Vector Targeting for Therapeutic Gene Delivery

How to Cite

Büning, H., Ried, M. U. and Hallek, M. (2002) Receptor Targeting of Adeno-Associated Virus Vectors, in Vector Targeting for Therapeutic Gene Delivery (eds D. T. Curiel and J. T. Douglas), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/0471234303.ch10

Editor Information

  1. Division of Human Gene Therapy, Departments of Medicine, Pathology and Surgery, and the Gene Therapy Center, The University of Alabama at Birmingham, USA

Author Information

  1. Genzentrum Ludwig-Maximilians-Universitat Munchen, Munchen, Germany

Publication History

  1. Published Online: 31 MAR 2003
  2. Published Print: 9 AUG 2002

ISBN Information

Print ISBN: 9780471434795

Online ISBN: 9780471234302

SEARCH

Keywords:

  • Adeno-Associated Virus;
  • AAV;
  • receptor targeting;
  • cell specific vectors;
  • capsid modification;
  • ligand insertion;
  • bispecific antibody

Summary

One of the most promising viral vectors is derived from the adeno-associated virus type 2 (AAV-2), a member of the parvovirus family. Since AAV-2 has a broad tissue tropism it is attractive for in vitro gene transfer into various tissues. However, the broad host range is a disadvantage for in vivo gene therapy, because a selective, tissue- or organ-restricted infection is desirable to enhance the safety and efficiency for the gene transfer in vivo. Therefore, increasing efforts are undertaken to retarget AAV-2 based vectors to specific receptors a summary of which is given in this review.